No effect of adding brief dynamic therapy to pharmacotherapy in the treatment of obsessive-compulsive disorder with concurrent major depression

Psychotherapy and Psychosomatics

Volumn 79, Issue 5, 2010, Pages 295-302

  Maina, Giuseppe ^a   Rosso, Gianluca ^a   Rigardetto, Sylvia ^a   Chiadò Piat, Simone ^a   Bogetto, Filippo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Brief dynamic therapy; Combined treatment; Major depressive disorder; Obsessive compulsive disorder; Selective serotonin reuptake inhibitors

Indexed keywords

FLUVOXAMINE; SERTRALINE;

ADULT; ARTICLE; BIOMETRY; BRIEF DYNAMIC THERAPY; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; HAMILTON SCALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER, MAJOR; FEMALE; FLUVOXAMINE; HUMANS; MALE; OBSESSIVE-COMPULSIVE DISORDER; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTHERAPY, BRIEF; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; TREATMENT OUTCOME;

EID: 77954274035     PISSN: 00333190     EISSN: None     Source Type: Journal    
DOI: 10.1159/000318296     Document Type: Article

References (36)

1. Rasmussen SA, Eisen JL: The epidemiology and differential diagnosis of obsessive-compulsive disorder. J Clin Psychiatry 1994; 55(suppl):5-10.
2. Hollander E, Greenwald S, Neville D, Johnson J, Hornig CD, Weissman MM: Uncomplicated and comorbid obsessive-compulsive disorder in an epidemiologic sample. Depress Anxiety 1999; 4:111-119.
3. Karno M, Golding JM, Sorenson SB, Burnam MA: The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry 1988; 45:1094-1099.
4. Kolada JL, Bland RC, Newman SC: Epidemiology of psychiatric disorders in Edmonton: obsessive-compulsive disorder. Acta Psychi-atr Scand 1994; 376(suppl):24-35.
5. Ruscio AM, Stein DJ, Chiu WT, Kessler RC: The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry 2010; 15: 53-63.
6. Weissman MM, Bland RC, Canino GJ, Greenwald S, Hwu HG, Lee CK, Newman SC, Oakley-Browne MA, Rubio-Stipec M, Wickramaratne PJ, Wittchen HU, Yeh EK: The cross-national epidemiology of obsessive-compulsive disorder. J Clin Psychiatry 1994; 55(suppl 3):5-10.
7. Denys D, Tenney N, Van Megen DJGM, de Geus F, Westenberg HGM: Axis I and II co-morbidity in a large sample of patients with obsessive-compulsive disorder. J Affect Dis-ord 2004; 80:155-162.
8. LaSalle VH, Kromer KR, Nelson KN, Kazu-ba D, Justement L, Murphy DL: Diagnostic interview assessed neuropsychiatric disorder comorbidity in 334 individuals with obsessive compulsive disorder. Depress Anxiety 2004; 19: 16 3-17 3.
9. Maina G, Albert U, Pessina E, Bogetto F: Bipolar obsessive-compulsive disorder and personality disorders. Bipolar Disord 2007; 9: 722-729.
10. Rasmussen SA, Eisen JL: The epidemiology and clinical features of obsessive-compulsive disorder. Psychiatr Clin North Am 1992; 15:74 3-758.
11. Abramowitz JS: Treatment of obsessive-compu lsive d is order in patients who have co-morbid major depression. J Clin Psychol 2004; 60:1133-1141.
12. Steketee G, Chambless DL, Tran GQ: Effect of axis I and II on behavior therapy outcome for obsessive-compulsive disorder and agoraphobia. Compr Psychiatry 2001; 42:76-86. (Pubitemid 32095068)
13. Ackerman DL, Greenland S, Bystritsky A, Morgenstern H, Katz RJ: Predictors of response in obsessive-compulsive disorder: multivariate analyses from a multicenter trial of clomipramine. J Clin Psychopharmacol 1994; 14: 247-254.
14. Rice E: Ref lections on the obsessive-compulsive disorders: a psychodynamic and therapeutic perspective. Psychoanal Rev 2004; 91: 23-44.
15. Kempe S, Luyten P: Psychodynamic and cognitive-behavioral approaches of obsessive-compulsive disorder: is it time to work through our ambivalence? Bull Menninger Clin 2007; 4:291-311.
16. Salminen JK, Karlsson H, Hietala J, Kajander J, Aalto S, Markkula J, Rasi-Hakala H, Toik-ka T: Short-term psychodynamic psychotherapy and fluoxetine in major depressive disorder: a randomized comparative study. Psychother Psychosom 2008; 77:351-357.
17. de Jonghe F, Kool S, Van Aalst G, Dekker J, Peen J: Combining psychotherapy and anti-depressant in the treatment of depression. J Affect Disord 2001; 64:217-229. (Pubitemid 32324214)
18. Burnand Y, Andreoli A, Kolatte E, Venturini A, Rosset N: Psychodynamic psychotherapy and clomipramine in the treatment of major depression. Psychiatr Ser v 2002; 53: 585-590.
19. Maina G, Rosso G, Crespi C, Bogetto F: Combined brief dynamic therapy and phar-macotherapy in the treatment of major depressive disorder: a pilot study. Psychother Psychosom 2007; 76: 298-305.
20. Maina G, Rosso G, Bogetto F: Brief dynamic therapy combined with pharmacotherapy in the treatment of major depressive disorder: long term results. J Affect Disord 2009; 114: 200-207.
21. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Health Disorder, ed 4. Washington, American Psychiatric Association, 1994.
22. First MB, Spitzer RI, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders. Washington, American Psychiatric Press, 1997.
23. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Hen-inger GR, Charney DS: The Yale-Brown Obsessive-Compulsive Scale. 1. Development, use and reliability. Arch Gen Psychiatry 1989; 46:1006-1011.
24. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, He-ninger GR, Charney DS: The Yale-Brown Obsessive-Compulsive Scale. 2. Validity. Arch Gen Psychiatry 1989; 46:1012-1016.
25. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6:278-296.
26. Malan DH: A Study of Brief Psychotherapy. London, Tavistock, 1963.
27. Horowitz M, Marmar C, Krupnik J, Wilner N, Kaltreider N, Wallerstein R: Personality Styles and Brief Psychotherapy. London, Jason Aronson, 1997.
28. First MB, Gibbon M, Spitzer RL, Williams JBW, Benjamin Smith L: Structured Clinical Interview for DSM-IV Axis II Disorders. Washington, American Psychiatric Press, 1997.
29. Malan DH: Toward a Validation of Dynamic Psychotherapy. A Replication. New York, Plenum, 1976.
30. French TM: The Integrations of Behavior; vol 3: The Reintegrative Process in a Psychoanalytic Treatment. Chicago, Chicago University Press, 1958.
31. French TM: The cognitive structure of behaviour; in Psychoanalytic Interpretations. The Selected Papers of Thomas M French. Chicago, Quadrangle, 1970, p 27.
32. Guy W: ECDEU Assessment Manual for Psy-chopharmacology, rev. Washington, US Department of Health, Education and Welfare, 1976, pp 76-338.
33. Jones SH, Thormicroft G, Coffey M, Dunn G: A brief mental health outcome scale.: reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry 1976; 166:654-659.
34. Kirkwood BR, Sterne JAC: Essential Medical Statistics, ed 2. Malden, Blackwell Science, 2006, chapt 35.
35. Mohr DC, Spring B, Freedland KE, Beckner V, Arean P, Hollon S, Ockene J, Kaplan R: The selection and design of control conditions for randomized controlled trials of psychological interventions. Psychother Psy-chosom 2009; 78:275-284.
36. Rutherford BR, Sneed JR, Roose SP: Does study design influence outcome? The effects of placebo and treatment duration in antide-pressant trials. Psychother Psychosom 2008; 78:1 72-1 8 1.